Jeffrey Hung Analyst PerformanceAnalyst at Morgan StanleyJeffrey Hung is a stock analyst at Morgan Stanley focused in the medical sector, covering 26 publicly traded companies. Over the past year, Jeffrey Hung has issued 49 stock ratings, including buy and hold recommendations. While full access to Jeffrey Hung's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Jeffrey Hung's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings93 Last 10 YearsBuy Recommendations70.00% 63 Buy RatingsCompanies Covered26 Unique Companies Ratings Distribution90RatingsDistribution of strong buy, buy, hold, and sell ratings by Jeffrey Hung.RatingPercentageCount Strong Buy0.0%0 ratings Buy70.0%62 ratings Hold27.8%25 ratings Sell2.2%2 ratingsOut of 90 total stock ratings issued by Jeffrey Hung at Morgan Stanley, the majority (70.0%) have been Buy recommendations, followed by 27.8% Hold and 2.2% Sell.Best & Worst CallsBest Call0000.0%ERASMar 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%ICPTSep 2016Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ100.0% of companies on NASDAQ26 companiesJeffrey Hung, an analyst at Morgan Stanley, currently covers 26 companies listed on , with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical25 companies96.2%Manufacturing1 company3.8%Jeffrey Hung of Morgan Stanley specializes in stock coverage within the Medical sector, with additional focus on Manufacturing companies.Coverage IndustriesIndustryPercentageMED - BIOMED/GENE18 companies69.2%MED - DRUGS5 companies19.2%Miscellaneous1 company3.8%PHARMACEUTICAL PREPARATIONS1 company3.8%BIOTECHNOLOGY1 company3.8% Jeffrey Hung's Ratings History at Morgan Stanley Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsCTNMContineum Therapeutics5/14/2026Boost Price Target$14.09$16.00Equal Weight$0.0000.00% ROICYTKCytokinetics5/6/2026Boost Price Target$74.10$103.00Overweight$0.0000.00% ROINBIXNeurocrine Biosciences5/6/2026Boost Price Target$144.93$191.00Equal Weight$0.0000.00% ROIRAREUltragenyx Pharmaceutical4/16/2026Boost Price Target$24.82$67.00Overweight$0.0000.00% ROINBIXNeurocrine Biosciences4/10/2026Boost Price Target$129.91$185.00Equal Weight$0.0000.00% ROIBCYCBicycle Therapeutics4/8/2026Lower Price Target$5.05$12.00Equal Weight$0.0000.00% ROIRYTMRhythm Pharmaceuticals3/17/2026Lower Price Target$90.51$136.00Overweight$0.0000.00% ROIJAZZJazz Pharmaceuticals2/25/2026Boost Price Target$190.04$226.00Overweight$0.0000.00% ROIPTCTPTC Therapeutics2/23/2026Boost Price Target$70.66$92.00Overweight$0.0000.00% ROIBIOABioAge Labs2/4/2026Set Price Target$20.05$23.00$0.0000.00% ROI Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. PTCTPTC Therapeutics1/8/2026Reiterated Rating$77.24$90.00Overweight$0.0000.00% ROIJAZZJazz Pharmaceuticals1/8/2026Reiterated Rating$169.37$225.00Overweight$0.0000.00% ROIERASErasca1/8/2026Set Price Target$5.17$4.00$0.0000.00% ROICGONCG Oncology1/8/2026Reiterated Rating$42.45$89.00Overweight$0.0000.00% ROICGEMCullinan Therapeutics1/8/2026Reiterated Rating$10.94$30.00Overweight$0.0000.00% ROICTNMContineum Therapeutics1/8/2026Reiterated Rating$9.56$14.00Equal Weight$0.0000.00% ROINBIXNeurocrine Biosciences1/8/2026Reiterated Rating$140.62$175.00Equal Weight$0.0000.00% ROICRNXCrinetics Pharmaceuticals1/6/2026Boost Price Target$44.67$80.00Overweight$0.0000.00% ROICYTKCytokinetics12/22/2025Boost Price Target$68.34$71.00Overweight$0.0000.00% ROIRYTMRhythm Pharmaceuticals12/11/2025Reiterated Rating$117.36$150.00Overweight$0.0000.00% ROIJAZZJazz Pharmaceuticals11/17/2025Boost Price Target$171.61$205.00Overweight$0.0000.00% ROIENGNenGene11/12/2025Boost Price Target$9.20$19.00Overweight$0.0000.00% ROINBIXNeurocrine Biosciences11/11/2025Lower Price Target$150.02$173.00Overweight$0.0000.00% ROIJAZZJazz Pharmaceuticals10/24/2025Set Price Target$138.52$183.00$0.0000.00% ROIJAZZJazz Pharmaceuticals10/20/2025Boost Price Target$136.06$180.00Overweight$0.0000.00% ROINBIXNeurocrine Biosciences10/20/2025Boost Price Target$141.95$168.00Overweight$0.0000.00% ROIRYTMRhythm Pharmaceuticals10/16/2025Boost Price Target$111.88$129.00Overweight$0.0000.00% ROICRNXCrinetics Pharmaceuticals9/29/2025Boost Price Target$44.04$77.00Overweight$0.0000.00% ROIRYTMRhythm Pharmaceuticals9/24/2025Boost Price Target$98.68$122.00Overweight$0.0000.00% ROIJAZZJazz Pharmaceuticals9/24/2025Boost Price Target$129.40$167.00Overweight$0.0000.00% ROICGONCG Oncology9/17/2025Boost Price Target$38.54$79.00Overweight$0.0000.00% ROIENGNenGene9/12/2025Lower Price Target$6.04$18.00Overweight$0.0000.00% ROINBIXNeurocrine Biosciences9/5/2025Boost Price Target$140.40$163.00Overweight$0.0000.00% ROIJAZZJazz Pharmaceuticals8/28/2025Boost Price Target$124.12$163.00Overweight$0.0000.00% ROIPTCTPTC Therapeutics8/20/2025Lower Price Target$48.61$71.00Overweight$0.0000.00% ROIERASErasca8/18/2025Reiterated Rating$1.64$2.00Equal Weight$0.0000.00% ROICTNMContineum Therapeutics8/18/2025Boost Price Target$7.38$21.00Overweight$0.0000.00% ROICGEMCullinan Therapeutics8/18/2025Lower Price Target$7.74$28.00Overweight$0.0000.00% ROIBCYCBicycle Therapeutics8/12/2025Lower Price Target$7.46$13.00Equal Weight$0.0000.00% ROIJAZZJazz Pharmaceuticals8/6/2025Lower Price Target$108.12$162.00Overweight$0.0000.00% ROIIran's New Leader Just Said Something That Should Terrify Every American (Ad)Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of the world's oil passing through that corridor, crude has already crossed $100 per barrel. History shows gold surged 571% during the 1973 oil crisis and 425% in 1979. Today, the U.S. holds 8,133 tonnes of gold valued on the books at $42.22 per ounce - while gold trades above $5,000. American Alternative Assets has released The Great Gold Reset report detailing what this gap could mean for investors.Claim your free copy of The Great Gold Reset report todayNBIXNeurocrine Biosciences7/31/2025Boost Price Target$129.40$158.00Overweight$0.0000.00% ROIJAZZJazz Pharmaceuticals7/22/2025Lower Price Target$114.72$165.00Overweight$0.0000.00% ROINBIXNeurocrine Biosciences7/22/2025Boost Price Target$132.79$150.00Overweight$0.0000.00% ROIFOLDAmicus Therapeutics7/17/2025Upgrade$6.07Overweight$0.0000.00% ROIRAREUltragenyx Pharmaceutical7/14/2025Lower Price Target$29.51$55.00Overweight$0.0000.00% ROICGONCG Oncology6/17/2025Boost Price Target$26.26$56.00Overweight$0.0000.00% ROIACADACADIA Pharmaceuticals5/20/2025Set Price Target$21.99$24.00Equal Weight$0.0000.00% ROICTNMContineum Therapeutics5/19/2025Lower Price Target$3.71$20.00Overweight$00.0000.00% ROICGONCG Oncology5/19/2025Lower Price Target$24.86$52.00Overweight$00.0000.00% ROIRAREUltragenyx Pharmaceutical5/9/2025Boost Price Target$35.87$65.00Overweight$00.0000.00% ROIJAZZJazz Pharmaceuticals5/7/2025Lower Price Target$104.98$166.00Overweight$000.0000.00% ROIENGNenGene3/11/2025Lower Price Target$4.97$34.00Overweight$0.0000.00% ROIIRONDisc Medicine3/7/2025Reiterated Rating$55.34$85.00Overweight$00.0000.00% ROICGEMCullinan Therapeutics3/7/2025Reiterated Rating$8.91$35.00Overweight$00.0000.00% ROICTNMContineum Therapeutics3/7/2025Reiterated Rating$6.43$25.00Overweight$00.0000.00% ROICGONCG Oncology3/7/2025Reiterated Rating$26.82$55.00Overweight$00.0000.00% ROICNTACentessa Pharmaceuticals3/7/2025Reiterated Rating$16.31$27.00Overweight$00.0000.00% ROIACADACADIA Pharmaceuticals3/7/2025Reiterated Rating$17.46$20.00Equal Weight$00.0000.00% ROIRYTMRhythm Pharmaceuticals3/7/2025Reiterated Rating$50.86$72.00Overweight$00.0000.00% ROIPTCTPTC Therapeutics3/7/2025Reiterated Rating$52.09$70.00Overweight$00.0000.00% ROINBIXNeurocrine Biosciences3/7/2025Reiterated Rating$113.38$150.00Overweight$000.0000.00% ROIJAZZJazz Pharmaceuticals3/7/2025Reiterated Rating$139.12$183.00Overweight$000.0000.00% ROIERASErasca3/7/2025Reiterated Rating$1.50$4.00Overweight$00.0000.00% ROICYTKCytokinetics2/13/2025Upgrade$42.18$67.00Overweight$00.0000.00% ROINBIXNeurocrine Biosciences2/4/2025Boost Price Target$150.10$185.00Overweight$000.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageWall Street ZenUBS GroupCitigroupBarclaysWells Fargo & CompanyMorgan StanleyRoyal Bank Of CanadaJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupTD CowenTruist FinancialPiper SandlerStifel NicolausRaymond James Financial Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
